Cargando…
Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function
Novel biotherapeutic glycoproteins, like recombinant monoclonal antibodies (mAbs) are widely used for the treatment of numerous diseases. The N-glycans attached to the constant region of an antibody have been demonstrated to be crucial for the biological efficacy. Even minor modifications of the N-g...
Autores principales: | Popp, Oliver, Moser, Samuel, Zielonka, Jörg, Rüger, Petra, Hansen, Silke, Plöttner, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825202/ https://www.ncbi.nlm.nih.gov/pubmed/29173063 http://dx.doi.org/10.1080/19420862.2017.1405203 |
Ejemplares similares
-
In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
por: Thomann, Marco, et al.
Publicado: (2015) -
IgG-Fc glycoengineering in non-mammalian expression hosts
por: Loos, Andreas, et al.
Publicado: (2012) -
Non-fucose level as a function of glycoenzyme transcription in a glycoengineered CHO cell line
por: Markert, Sven, et al.
Publicado: (2015) -
Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines
por: Li, Jing, et al.
Publicado: (2019) -
Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions
por: Lindemann, Carsten, et al.
Publicado: (2013)